Posted by Michael Wonder on 12 Apr 2017
HAS publishes Transparency Commission opinion for Keytruda
12 April 2017 - The opinion relates the use of pembrolizumab by patients with non-small-cell lung cancer.
The clinical service provided by pembrolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer is important.
The Commission considers that pembrolizumab provides a minor improvement in medical benefit (ASMR IV) compared with docetaxel for the treatment of adults with locally advanced or metastatic non-small-cell lung cancer with PD-L1 tumors (= 1%) after the use/failure of prior chemotherapy.
